Talimogene laherparepvec - Biologic Drug Details

Summary for talimogene laherparepvec

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for talimogene laherparepvec

Recent Clinical Trials for talimogene laherparepvec

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Binhui Biopharmaceutical Co., Ltd.	PHASE1
John Rieth	PHASE2
Amgen	PHASE2

See all talimogene laherparepvec clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for talimogene laherparepvec Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for talimogene laherparepvec Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2033-08-30	DrugPatentWatch analysis and company disclosures
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2037-07-25	DrugPatentWatch analysis and company disclosures
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-09-07	DrugPatentWatch analysis and company disclosures
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2033-08-02	DrugPatentWatch analysis and company disclosures
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-06-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-10-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for talimogene laherparepvec Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2033-08-30	Patent claims search
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2037-07-25	Patent claims search
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-09-07	Patent claims search
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2033-08-02	Patent claims search
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-06-01	Patent claims search
Amgen Inc.	IMLYGIC	talimogene laherparepvec	For Injection	125518		2038-10-25	Patent claims search

International Patents for talimogene laherparepvec

Country	Patent Number	Estimated Expiration
China	114129567
Australia	2694701
Japan	6457940
Mexico	386321
European Patent Office	2177619
Australia	2013296233

Supplementary Protection Certificates for talimogene laherparepvec

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
93101	Luxembourg		PRODUCT NAME: IMLYGIC - TALIMOGENE LAHERPAREPVEC; FIRST REGISTRATION DATE: 20151218
16C0026	France		PRODUCT NAME: TALIMOGENE LAHERPAREPVEC; REGISTRATION NO/DATE: EU/1/15/1064 20151218
122016000047	Germany		FORMER OWNER: BIOVEX LIMITED, OXFORD, GB
132016000061404	Italy		PRODUCT NAME: TALIMOGENE LAHERPAREPVEC(IMLYGIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1064, 20151218
1690028-4	Sweden		PRODUCT NAME: TALIMOGENE LAHERPAREPVEC; REG. NO/DATE: EU/1/15/1064 20151218
C01252322/01	Switzerland		PRODUCT NAME: TALIMOGEN LAHERPAREPVEC; REGISTRATION NO/DATE: SWISSMEDIC 65812 13.07.2016

Market Dynamics and Financial Trajectory for Talimogene Laherparepvec

Last updated: February 15, 2026

Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex virus type 1 designed for intratumoral injection. Approved by the FDA in October 2015 for melanoma treatment, it is marketed as Imlygic.

---

Market Penetration and Adoption

Indications and Approved Uses:
T-VEC is indicated for unresectable melanoma recurrent after surgery. Its approval covers Stage III and selected Stage IV melanoma. It is the first oncolytic virus therapy approved in the U.S., establishing a unique position in immuno-oncology.

Market Share:
Since launch, T-VEC's market share remains limited. In 2021, it accounted for approximately 2-3% of the melanoma treatment market, primarily due to sparse adoption related to:

• Limited efficacy in advanced disease stages
• The need for intratumoral injections requiring specialized administration
• Competition from ICIs (immune checkpoint inhibitors) like pembrolizumab and nivolumab

Competitive Landscape:
Key competitors include:

• Checkpoint inhibitors (PD-1/PD-L1 inhibitors):
  These agents dominate melanoma therapy with response rates surpassing 40%. They are administered systemically, providing broader treatment options.

• Other oncolytic virus therapies:
  Currently, no other US-approved oncolytic virus drugs compete directly.

• Emerging therapies:
  Research into combination regimens with T-VEC and ICIs (e.g., T-VEC + pembrolizumab) has shown promising response rate improvements but remains investigational. The potential therapy landscape shift depends on these trial outcomes.

---

Market Drivers and Restraints

Drivers:

• First-mover advantage as an oncolytic virus:
  T-VEC is the first approved oncolytic immunotherapy, providing a foundation for further development.

• Combination therapy potential:
  Trials combining T-VEC with checkpoint inhibitors suggest increased response rates, which could expand its therapeutic role.

• Growing melanoma incidence:
  The U.S. melanoma incidence increased from 22.4 per 100,000 in 2009 to 25.4 in 2018 (SEER data). Growth could drive overall demand.

Restraints:

• Limited efficacy in advanced disease:
  T-VEC shows modest response rates (around 16%) in metastatic melanoma, restricting its use to select cases.

• Application constraints:
  Intratumoral injections are suitable for accessible lesions, limiting application to certain patients.

• Competitive and market saturation pressures:
  The dominance of systemic immunotherapies and targeted agents reduces T-VEC's market share.

---

Financial Trajectory and Revenue Projections

Historical Revenue Data:
Global sales peaked near $40 million in 2019, with minor declines in subsequent years, reflecting modest uptake (Evaluate Pharma data). Market penetration remains limited, with only select patients eligible.

Forecasts (2023-2028):
Projections depend heavily on:

• Approval expansion:
  If T-VEC receives approval for additional indications, such as other melanoma stages or cutaneous metastases, revenue could increase substantially.

• Combination therapy approval:
  Favorable trial outcomes could lead to label extensions or co-approval with checkpoint inhibitors, potentially doubling or tripling revenue streams.

• Market evolution:
  With new oncolytic virus agents entering development and AIs maintaining dominance, T-VEC's growth may stay restrained.

Estimated cumulative revenues over five years could range from $200 million to over $500 million, driven by increased adoption in combination regimens. Risk factors include the slow pace of clinical approvals, safety concerns, and the competitive landscape's rapid evolution.

---

Regulatory and Commercial Outlook

Ongoing Trials:

• A Phase 3 trial combining T-VEC with pembrolizumab showed improved overall response rates (ORR up to 62% in combination vs. 33% with pembrolizumab alone).
• Trials examining T-VEC in earlier melanoma stages and other cancers (e.g., head and neck) suggest planned expansion but face regulatory and clinical hurdles.

Regulatory Challenges:
Approval for additional indications could expand market access. However, beyond melanoma, T-VEC's efficacy remains under scrutiny.

Commercial Strategy:
Focusing on combination therapies and specific lesion types may optimize market penetration. Direct-to-consumer educational efforts are limited given the injection-based administration.

---

Summary

Talimogene laherparepvec remains a niche therapy within melanoma. While it pioneers the oncolytic virus class, its market share remains constrained by efficacy, administration complexity, and competition from systemic immunotherapies. Future growth hinges on successful clinical trial outcomes, potential label extensions, and integration into combination treatment protocols.

---

Key Takeaways

• T-VEC's peak global sales in 2019 reached approximately $40 million.
• Its market penetration is limited due to modest efficacy and administration constraints.
• Combination studies with checkpoint inhibitors indicate potential for expanding its use.
• Revenue forecasts over five years range from $200 million to $500 million, contingent on regulatory and clinical milestones.
• The competitive landscape favors systemic immunotherapies with broader applicability.

---

FAQs

1. What are the main limitations of T-VEC?
Limited efficacy in metastatic melanoma, need for intratumoral injections, and competition from systemic immunotherapies restrict its use.

2. Can T-VEC be used in combination with other therapies?
Yes. Trials combining T-VEC with immune checkpoint inhibitors have shown improved response rates, potentially expanding its role.

3. What is the outlook for T-VEC in the next five years?
Positive if combination therapies gain approval and trials demonstrate efficacy in broader indications, leading to increased sales.

4. How has the competition affected T-VEC’s market share?
Checkpoint inhibitors dominate melanoma treatment, reducing T-VEC’s share despite its unique mechanism.

5. Are there prospects for expanding T-VEC beyond melanoma?
Ongoing trials are exploring use in other cancers, such as head and neck, but regulatory approval remains uncertain.

---

References

1. [1] FDA. (2015). Imlygic (talimogene laherparepvec) Label.
2. [2] Evaluate Pharma. (2021). Oncology Market Data.
3. [3] SEER Program. (2020). Melanoma Incidence Data.
4. [4] National Cancer Institute. (2022). Melanoma Treatment Summary.
5. [5] ClinicalTrials.gov. (2023). T-VEC Clinical Trial Listings.